ArticleJournal of substance use and addiction treatment2026
Would we, could we? Measuring attitudinal and capacity barriers to supporting recovery housing residents on medication for opioid use disorder.
Article in Journal of substance use and addiction treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRecovery housing provides critical support for individuals with opioid use disorder (OUD), yet residents who use medications for OUD (MOUD) often face barriers to entry and long-term support. No existing validated instruments currently assess these barriers, which can differ by MOUD type and reflect both attitudinal stigma and logistical capacity within recovery housing settings.
methodsWe developed and tested two parallel versions (Operator and Resident) of a novel tool, the Recovery Housing Barriers to Medications for Addiction Treatment (RHB-MAT) measure. Item generation was informed by literature review and structured input from current housing operators and residents, resulting in scales addressing attitudinal barriers (for both operators and residents) and capacity barriers (for operators) and MOUD type (buprenorphine, methadone, naltrexone). Surveys were administered to 145 recovery housing operators and 250 residents across the United States. Exploratory and confirmatory factor analyses were conducted to establish dimensionality. Internal consistency, and convergent, divergent, and concurrent criterion validity were examined using established measures of stigma and related constructs.
resultsFactor analyses supported a multidimensional structure, distinguishing attitudinal barriers across both groups and capacity barriers among operators. Internal consistency across scales was acceptable to strong (α = 0.74-0.92) across all but one subscale. Convergent validity was supported while divergent validity was less consistent. Concurrent criterion validity was generally demonstrated with associations between Operator RHB-MAT scores and their house's unique medication acceptance policies by MOUD type. Overall, residents evidenced higher attitudinal barrier scores than operators.
conclusionsThe RHB-MAT represents the first validated measure of MOUD-related barriers in recovery housing, with tailored versions for both operators and residents. This tool can be used in research, policy, and practical quality improvement efforts to identify and address attitudinal and capacity-related barriers that impede access to evidence-based OUD treatment in recovery residences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.